Alice Tsang Shaw, MD, PhD, and Tony Mok, MD, on NSCLC: Results From the ALEX and ARCHER 1050 Trials

2017 ASCO Annual Meeting
Tweet this page

Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital, and Tony Mok, MD, of the Chinese University of Hong Kong, discuss their two ASCO-featured abstracts on non–small cell lung cancer: alectinib vs crizotinib in treatment-naive advanced ALK+ disease, and dacomitinib vs gefitinib for first-line treatment of advanced EGFR+ disease. (Abstracts LBA9008 and LBA9007)

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.